Assessment of the Axone Micro Quadripolar Lead for Enhanced Cardiac Resynchronization Therapy (ASTRAL-4LV)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04463641|
Recruitment Status : Recruiting
First Posted : July 9, 2020
Last Update Posted : January 11, 2021
|Condition or disease||Intervention/treatment||Phase|
|Heart Failure Cardiac Resynchronization Therapy||Device: Implantation of the Axone 4LV Lead||Not Applicable|
This is a interventional, pivotal, prospective, single arm, open label, multicenter, international trial.
The device under investigation is the Axone system, consisting of:
- Axone 4LV: an ultrathin, lumenless, quadripolar, IS4-compatible lead designed for left ventricular pacing for cardiac resynchronization therapy (CRT).
- Axone µGuide: a dedicated, permanently implantable micro catheter designed for implantation of the Axone 4LV lead.
The primary endpoint data will be used to support CE marking of the Axone system.
The primary endpoints will be evaluated at 6 months post-implantation. Subjects will be followed-up at 6 weeks, 3 months, 6 months, 12 months post-implantation, then yearly until 4 years post-implantation.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||152 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Assessment of the Axone Micro Quadripolar Lead for Enhanced Cardiac Resynchronization Therapy|
|Actual Study Start Date :||December 3, 2020|
|Estimated Primary Completion Date :||July 2022|
|Estimated Study Completion Date :||December 2025|
Experimental: Axone 4LV Lead
Subjects implanted with the Axone 4LV Lead
Device: Implantation of the Axone 4LV Lead
Implantation of the Axone 4LV Lead
- Safety co-primary endpoint, defined as Axone system related complication free rate at 6 months post implant [ Time Frame: 6 months ]A complication is defined as any Serious Adverse Device Effect (SADE) resulting in death or requiring invasive intervention. Safety co-primary endpoint assessment will be based on independent event adjudication by a Clinical Event Committee (CEC).
- Performance co-primary endpoint, defined as LV pacing success rate at 6 months post implant [ Time Frame: 6 months ]
LV pacing success is defined as at least one LV pacing vector with:
- Pacing Threshold (PT) ≤ 3.5V at 1ms pulse width, and
- No phrenic nerve stimulation at PT+2V / 1ms pulse width.
- Bizone LV pacing success rate at 6 months post implant [ Time Frame: 6 months ]
Bizone LV pacing success is defined as two distant pacing vectors with:
- A Pacing Threshold (PT) ≤ 3.5V at 1ms pulse width, and
- No phrenic nerve stimulation at PT +2V / 1ms pulse width. Two pacing vectors are considered distant when cathode electrodes are separated by at least 30 mm.
- Axone 4LV implantation success rate [ Time Frame: At implant, preferably within 15 days of enrollment ]
- Implantation duration [ Time Frame: At implant, preferably within 15 days of enrollment ]
- Fluoroscopy time [ Time Frame: At implant, preferably within 15 days of enrollment ]Fluoroscopy time is measured in minutes
- Fluoroscopy dose [ Time Frame: At implant, preferably within 15 days of enrollment ]Fluoroscopy dose is measured using dose area product (Gray.cm^2)
- Axone system handling assessment [ Time Frame: At implant, preferably within 15 days of enrollment ]Implanters will be asked to fill in a handling questionnaire and record observations related to the use of the Axone system.
- Axone implanters' learning curve [ Time Frame: At implant, preferably within 15 days of enrollment ]This endpoint will be based on fluoroscopy time for implantation. The effect of removing the 1st, 2nd, 3rd, etc implanted subjects on mean fluoroscopy time (per implanter and per site) will be calculated.
- Number of excitable myocardium areas at implant [ Time Frame: At implant, preferably within 15 days of enrollment ]"Excitable myocardium areas" are areas that can be paced by the implanted Axone 4LV lead.
- Effect of CRT therapy, in particular bizone pacing, on QRS parameters, at discharge and 6 months post implant [ Time Frame: At discharge, within 7 days of implant, and at 6 months ]The effect of monozone and bizone CRT pacing on duration of QRS is measured in milliseconds.
- Effect of CRT therapy, in particular bizone pacing, on Left Pre-Ejection Interval (LPEI), at discharge [ Time Frame: At discharge, within 7 days of implant ]LPEI (in milliseconds) is an electromechanical parameter that can be assessed using echocardiography.
- Axone 4LV lead pacing threshold [ Time Frame: Discharge (within 7 days of implant), 6 weeks, 3 months, 6 months, 12 months, 24 months 36 months, 48 months ]Pacing threshold is measured in Volts.
- Axone 4LV lead pacing impedance [ Time Frame: Discharge (within 7 days of implant), 6 weeks, 3 months, 6 months, 12 months, 24 months 36 months, 48 months ]Pacing impedance is measured in Ohms.
- Presence of phrenic nerve stimulation (PNS) with the Axone 4LV lead [ Time Frame: Implant (preferably within 15 days of enrollment), discharge (within 7 days of implant), 6 weeks, 3 months, 6 months ]The presence of PNS will be assessed at 10V using an external pacing system analyzer at implant, or at pacing threshold +2V at other visits.
- Axone 4LV lead programming [ Time Frame: Discharge (within 7 days of implant), 6 weeks, 3 months, 6 months, 12 months, 24 months 36 months, 48 months ]Lead programming will be reported using: (i) pacing amplitude (Volts), pulse width (milliseconds) and pacing vector(s) selected.
- Energy consumption associated with Axone 4LV lead [ Time Frame: 6 months ]Energy will be calculated using the formula: E=(pacing amplitude^2 x pulse width)/impedance. Energy, pacing amplitude, pulse width and impedance are measured in Joules, Volts, milliseconds, and Ohms, respectively.
- Axone system-related annual complication-free rate [ Time Frame: 12 months, 24 months 36 months, 48 months ]Definition of Axone system related complication is the same as for primary safety endpoint.
- Clinical response to CRT at 12 months post implant [ Time Frame: 12 months ]
Clinical response will be determined by looking at functional improvement, reverse remodelling, freedom from heart failure events, and rate of non-responders:
(i) functional improvement is defined as improvement in ≥1 NYHA (New York Heart Association) class from baseline to 12 months.
(ii) reverse remodelling is a ≥12% increase in left ventricular end systolic volume index (LVESVi: LVESV [mL] and body surface area [m^2] will be combined to report LVESVi).
(iii) freedom from heart failure events is defined as an absence of death or HF hospitalization.
(iv) non-responders are all those who are not responders. A responder is defined as a subject that is not dead and who did not experience any HF hospitalization and that has a stable or improved NYHA class versus baseline.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04463641
|Contact: Anaïs Balland, MScemail@example.com|
|CHRU Hopital Trousseau||Not yet recruiting|
|Contact: Bertrand Pierre, MD|
|CHU de Clermont-Ferrand||Recruiting|
|Contact: Frédéric Jean, MD|
|CHRU de Lille - Hôpital Cardiologique||Not yet recruiting|
|Contact: Christelle Marquié, MD|
|CHU Pontchaillou||Not yet recruiting|
|Contact: Christophe Leclercq, MD|
|CHU de Rouen||Recruiting|
|Contact: Frédéric Anselme, MD|
|Principal Investigator:||Frédéric Anselme, MD||CHU de Rouen, France|